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Introduction
Patients with variceal gastrointestinal bleeding are encounter-
ed daily in endoscopic departments around the world. Risk fac-
tors include infectious diseases such as hepatitis B and C virus
and schistosomiasis, as well as alcohol consumption and meta-
bolic syndrome with development of nonalcoholic fatty liver
disease [1]. Globally, prevalence and incidence of chronic liver
disease and cirrhosis varies markedly between countries [2].
High-quality epidemiological data from the majority of African
countries are lacking; nevertheless, development of cirrhosis
and related consequences are a major burden for public health
systems in the continent [2–4]. In Africa, mortality from cirrho-
sis is estimated at 12.9 to 24.2 per 100,000 person-years range
and prevalence of hepatitis B virus is among the highest in the
world at 6,100 per 100,000 inhabitants [5, 6].
The latest update of the Baveno guideline describes in detail
how to prevent and manage variceal bleeding, as well as how to
avoid recurrent bleeding [7]. The majority of recommendations
in the guideline are based on high levels of evidence and many
years of practice. However, some of the recommendations are
resource-sensitive and may be unavailable in low-resource set-
tings due to factors such as extensive costs, lack of sufficient
health professional training and logistical limitations.
The European Society of Gastrointestinal Endoscopy (ESGE)
has implemented a cascade methodology in a joint effort with
the World Endoscopy Organization (WEO), aiming to adapt ex-
isting guidelines to make them applicable to resource-limited
regions (including some African countries) [8]. Previously, two
cascade guidelines have been published focusing on endo-
scopic management of non-variceal upper gastrointestinal
bleeding and upper gastrointestinal obstruction, respectively
[8–10]. This ESGE cascade guideline aims to standardize endo-
scopic management of patients with variceal gastrointestinal
bleeding.
Methods
The methodology of the cascade guidelines has been described
in the ESGE position paper [8]. Briefly, endoscopy-related state-
ments from the Baveno VI guideline were extracted after agree-
ment with the European Association for the Study of Liver [7].
Following that step, members of the International Affairs Work-
ing Group (IAWG) independently categorized the statements as
resource-sensitive or not. Those with an agreement of 50% or
more for being resource-sensitive were selected for the revision
process and subsequently, adaptions were suggested for the
four previously defined resource levels (▶Table 1) [8]. The se-
lection of statements, as well as the adaption process, was
guided by an external panel of five colleagues from Nigeria,
Ghana, and Ethiopia, as well as collaborating WEO outreach
committee members.
The modified statements were then subject to a Delphi pro-
cess with local doctors invited by a dedicated mailing list repre-
sentative of gastroenterology specialists in different areas of
Africa, where a rate of agreement of 75% or higher of all adap-
tions for all resource levels led to acceptance of the cascade
statement [11]. If a 75% agreement was not reached, the state-
ment was subject to another round of modification before a fi-
nal Delphi process was carried out.
Results
Cascade statements
Statement selection: 50 of 199 statements from the original
BAVENO VI guideline were selected as resource-sensitive. Three
adapted cascade statements – one for each level, excluding the
IV as corresponding to the original guideline – were created for
each of the original recommendations, making a total of 150
adapted cascade guideline statements.
Delphi process: Overall, 205 experts showed an interest in
participating in the Delphi process. Finally, 38 experts from 16
countries participated in the Delphi process, expressing their
degree of agreement with one or more recommendations. De-
tails of the participants are provided in ▶Table 2. A ≥75%
agreement was achieved for 49 of 50 proposed adaptations.
▶Table 1 Level of treatment care.
I: Basic Core resources or fundamental services absolutely necessary for an endoscopy care system to function. By definition, a health care
system lacking any basic level resource would be unable to provide endoscopic service to its patient population. It includes diag-
nostic procedures (gastroscopy and colonoscopy) as well and fundamental monitoring abilities (blood pressure, basic
blood biochemistry).
II: Limited Second-tier resources or services that produce major improvements in outcome, such as increased survival, but that are attainable
with limited financial means andmodest infrastructure. It includesminor endoscopic procedures to improvemajor clinical outcomes
(i. e. sclerotherapy/adrenaline injection, band ligation, plasma expanders, basic surgical interventions).
III: Enhanced Third-tier resources or services that are optional but important. Enhanced-level resources may produce minor improvements in
outcome but increase the number and quality of therapeutic options. Most procedures that improves clinical outcome are available
(i. e. biliopancreatic endoscopy, electrosurgical unit, polypectomy/mucosectomy, anaesthesia back-up).
IV: Maximal High-level resources or services that may be used in some high-resource countries or be recommended in guidelines that assume
unlimited resources. To be useful, maximal-level resources typically depend on the existence and functionality of all lower-level re-
sources.
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One cascade adaptation recommendation on the role of cov-
ered self-expanding metal stents (C-SEMS) for refractory bleed-
ing failed to achieve the ≥75% agreement level. The comments
provided by the participants pointed towards the unavailability
of C-SEMS and balloon tamponade for treatment of refractory
variceal bleeding. For that reason, the statements were revised
to include best supportive care and non-selective beta blocker
(NSBB) treatment in Levels I and II.
Cascade adaptation: Each original recommendation with the
accepted adaptations is reported in ▶Table 3. It was assumed
that basic endoscopy is available at all levels of care. However,
added to the availability of endoscopy, some specific resources




3. Interventional radiology and surgery
4. Pharmacological treatment
At the basic level, best supportive care and NSBB treatment
were recommended as adaptations for primary as well as sec-
ondary prophylaxis of variceal hemorrhage. Octreotide was the
recommended adaptation when urgent endoscopic treatment
of active bleeding episodes was not available.
1. Endoscopic treatment
a) Esophageal varices
At the most basic level, band ligation of varices is the
treatment of choice in our adaptation. It is available in
most centers and represents the most effective endo-
scopic treatment for acute esophageal variceal bleeding
and for secondary prophylaxis. However, round-the-clock
availability of emergency endoscopic services may be
limited, representing the main difference between Levels
I and II. Thus, timing of endoscopy may be delayed,
worsened by a lack of availability of blood transfusion at
Level 1. Thus, we recommended as a possible adaptation
use of octreotide and supportive care.
b) Gastric varices
Injection of tissue adhesive (cyanoacrylate) does not re-
quire a high level of technical expertise. Unfortunately, it
is not available at the basic and limited levels. For that
reason, treatment of acute bleeding from isolated gastric
varices with band ligation can be considered even though
evidence for this procedure is limited [12].
c) Refractory bleeding
For endoscopic rescue treatment, balloon tamponade and
SEMS are not available at the basic level. They can be re-
commended only in some centers at the limited level, but
in all centers at the enhanced level.
2. Radiologic and surgical treatment
Transjugular intrahepatic portosystemic shunt (TIPS), balloon-
occluded retrograde transvenous obliteration (BRTO), and sur-
gical options such as the mesenteric-left portal vein bypass
(Meso-Rex operation) are not available except at the enhanced
resource level. For prevention of recurrent variceal hemor-
rhage, maximal endoscopic and pharmacological treatment
options should be exhausted.
Endoscopic treatment of gastroesophageal varices repre-
sents by far the most life-saving endoscopic intervention in
most of developing African countries given the high prevalence
of viral and parasitic liver infections. For that reason, primary
endoscopic treatment – i. e. band ligation – has become avail-
able also at Level II in most centers, providing a favorable prog-
nosis for patients with active bleeding. However, technical fea-
sibility may be hampered by irregular provision of endoscopic
resources such as training, scope maintenance, and availability
of ligators.
Despite endoscopy’s prominent role in this condition, re-
sources for it are not easily accessible for most patients with
gastroesophageal varices due to limited capacity, long distan-
ces or costs. In this context, use of NSBB is consistently recom-
mended through Level I and II as a less effective but more wide-
ly available resource.
Treatment of gastric varices remains challenging. The main
priority is adequate and cost-effective supply of tissue adhesive
to developing countries as the technical feasibility for its injec-
tion is available. Alternatively, band ligation or NSBB may repre-
sent surrogate treatments.
Conclusion
In conclusion, endoscopic treatment of variceal bleeding repre-
sents the most life-saving endoscopic intervention in most de-
veloping countries. In a resource-limited situation, adaptation
of general guidelines may help optimize endoscopic care in
this patient group.




North Africa (%) 20 (52.6%)
Central Africa (%)  3 (7.9%)
East Africa (%)  6 (15.8%)
West Africa (%)  8 (21%)
South Africa (%)  1 (2.6%)
Socioeconomic status of institution/hospital
High (%)  1 (2.6%)
Mid (%) 14 (36,8%)
Low (%) 23 (60.5%)
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▶Table 3 Adaptation of recommendations according to level of treatment care.
Original statements Suggested modifications
Surveillance of esophageal varices
 1 In compensated patients with no varices at screening endoscopy and with ongoing
liver injury (e. g. active drinking in alcoholics, lack of SVR in HCV), surveillance
endoscopy should be repeated at 2-year intervals.
Level I/II/III: No adjustment
 2 In compensated patients with small varices and with ongoing liver injury (e. g. active
drinking in alcoholics, lack of SVR in HCV), surveillance endoscopy should be re-
peated at 1-year intervals.
Level I/II/III: No adjustment
 3 In compensated patients with no varices at screening endoscopy in whom the ae-
tiological factor has been removed (e. g. achievement of SVR in HCV; long-lasting
abstinence in alcoholics) and who have no co-factors (e. g. obesity), surveillance
endoscopy should be repeated at three year intervals.
Level I/II/III: No adjustment
 4 In compensated patients with small varices at screening endoscopy in whom the
etiological factor has been removed (e. g. achievement of SVR in HCV; long-lasting
abstinence in alcoholics) and who have no co-factors (e. g. obesity), surveillance
endoscopy should be repeated at 2-year intervals).
Level I/II/III: No adjustment
Patients with no varices or small varices
 5 Patients with small varices with red whale marks or Child-Pugh C class have an in-
creased risk of bleeding and should be treated with non-selective beta blockers
(NSBB).
Level I/II/III: No adjustment
 6 Patients with small varices without signs of increased risk may be treated with NSBB
to prevent bleeding. Further studies are required to confirm their benefit.
Level I/II/III: No adjustment
Patients with medium-large varices
 7 Either NSBB or endoscopic band ligation is recommended for the prevention of the
first variceal bleeding of medium or large varices.
Level I: NSBB and endoscopic surveillance every
6 months
Level II: No adjustment
Level III: No adjustment
 8 The choice of treatment should be based on local resources and expertise, patient
preference and characteristics, contraindications and adverse events.
Level I/II/III: No adjustment
Patients with gastric varices
 9 Although a single study suggested that cyanoacrylate injection is more effective
than beta blockers in preventing first bleeding in patients with large gastroesopha-
geal varices type 2 or isolated gastric varices type 1, further studies are needed to
evaluate the risk/benefit ratio of using cyanoacrylate in this setting before a recom-
mendation can be made).
Level I: NSBB
Level II: NSBB and sclerotherapy e. g. submucosal
ethanol injection
Level III: No adjustment
Management of the acute bleeding episode
Blood volume restitution
10 The goal of resuscitation is to preserve tissue perfusion. Volume restitution should
be initiated to restore and maintain hemodynamic stability.
Level I/II/III: No adjustment
11 Packed red blood cells transfusion should be done conservatively at a target hae-
moglobin level between 7 and 8g/ dl, although transfusion policy in individual
patients should also consider other factors such as cardiovascular disorders, age,
hemodynamic status and ongoing bleeding).
Level I: Blood pressure monitoring and fluid resusci-
tation with crystalloid fluids
Level II: Restrictive blood transfusion strategy based
on clinical judgement
Level III: No adjustment
12 Recommendations regarding management of coagulopathy and thrombocytopenia
cannot be made on the basis of currently available data.
Level I/II/III: No adjustment
13 PT/INR is not a reliable indicator of the coagulation status in patients with cirrhosis. Level I/II/III: No adjustment
Antibiotic prophylaxis
14 Antibiotic prophylaxis is an integral part of therapy for patients with cirrhosis pre-
senting with upper gastrointestinal bleeding and should be instituted from admis-
sion.
Level I: No adjustment
Level II: No adjustment
Level III: No adjustment
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▶Table 3 (Continuation)
Original statements Suggested modifications
15 The risk of bacterial infection and mortality are very low in patients with Child-Pugh
A cirrhosis, but more prospective studies are needed to assess whether antibiotic
prophylaxis can be avoided in this subgroup of patients.
Level I/II/III: No adjustment
16 Individual patient risk characteristics and local antimicrobial susceptibility patterns
must be considered when determining appropriate first line acute variceal hemor-
rhage antimicrobial prophylaxis at each center.
Level I/II/III: No adjustment
17 Intravenous ceftriaxone 1g/24 h should be considered in patients with advanced
cirrhosis, in hospital settings with high prevalence of quinolone-resistant bacterial
infections and in patients on previous quinolone prophylaxis.
Level I: Intravenous antibiotics after local preferen-
ces and availability
Level II: No adjustment
Level III: No adjustment
Prevention of hepatic encephalopathy
18 Recent studies suggest that either lactulose or rifaximin may prevent hepatic ence-
phalopathy in patients with cirrhosis and upper gastrointestinal bleeding. However,
further studies are needed to evaluate the risk/benefit ratio and to identify high risk
patients before a formal recommendation can be made.
Level I: Lactulose and antibiotics according to local
preferences and availability
Level II: Lactulose and nonabsorbable antibiotics
Level III: No adjustment
19 Although, there are no specific studies in acute variceal bleeding, it is recommended
to adopt the recent EASL/AASLD HE guidelines which state that episodic HE should
be treated with lactulose (25ml q 12h until 2–3 soft bowel movements are pro-
duced, followed by dose titration to maintain 2–3 soft bowel movements per day).
Level I: Lactulose and best supportive care
Level II: No adjustment
Level III: No adjustment
20 Child-Pugh class C, the updated MELD score, and failure to achieve primary hae-
mostasis are the variables most consistently found to predict six week mortality.
Level I/II/III: No adjustment
Pharmacological treatment




Level III: No adjustment
22 Vasoactive drugs (terlipressin, somatostatin, octreotide) should be used in combi-
nation with endoscopic therapy and continued for up to five days.
Level I: Octreotide
Level II: Octreotide and endoscopic therapy is
recommended
Level III: No adjustment
23 Hyponatremia has been described in patients under terlipressin, especially in pa-
tients with preserved liver function. Therefore, sodium levels must be monitored.
Level I/II/III: No adjustment
Endoscopy
24 Following hemodynamic resuscitation, patients with upper gastrointestinal bleed-
ing and features suggesting cirrhosis should undergo esophagogastroduodenosco-
py within 12 h of presentation.
Level I. Technical expertise may not be available on
a 24 /7 basis
Level II. Endoscopy within 24 hours; trained emer-
gency team with necessary technical expertise
available
Level III. No adjustment
25 In the absence of contraindications (QT prolongation), pre-endoscopy infusion of
erythromycin (250mg IV 30–120min before endoscopy) should be considered.
Level I: Endoscopy even when pre-endoscopic ery-
thromycin infusion is not available.
Level II: No adjustment
Level III: No adjustment
26 The availability both of an on-call gastrointestinal endoscopist proficient in endo-
scopic haemostasis and on-call support staff with technical expertise in the usage of
endoscopic devices enables performance of endoscopy on a 24 /7 basis and is re-
commended.
Level I. Technical expertise may not be available on
a round-the clock basis
Level II. Endoscopy within 24 hours; trained emer-
gency team with necessary technical expertise
available
Level III. No adjustment
27 Patients with acute variceal hemorrhage should be considered for ICU or other well
monitored units.
Level I: Best supportive care
Level II: Best supportive care with best available
monitoring of vital parameters
Level III: No adjustment
E994 Karstensen John Gásdal et al. Endoscopic treatment of… Endoscopy International Open 2020; 08: E990–E997
Guideline
▶Table 3 (Continuation)
Original statements Suggested modifications
28 In patients with altered consciousness, endoscopy should be performed with pro-
tection of the airway.
Level I: Patients with ongoing active hematemesis
should be placed in a stable side position immedi-
ately; continuous active suction of blood and gastric
contents
Level II: Stable side position; continuous sedation;
continuous active suction of blood and gastric con-
tents; emergency endoscopy
Level III: No adjustment
29 Ligation is the recommended form of endoscopic therapy for acute oesophageal
variceal bleeding.
Level I: Best supportive and octreotide
Level II: No adjustment
Level III: No adjustment
30 Endoscopic therapy with tissue adhesive (e. g. N-butyl-cyanoacrylate) is recom-
mended for acute bleeding from isolated gastric varices (IGV) and those gastro-
esophageal varices type 2 (GOV2) that extend beyond the cardia.
Level I: Best supportive care and NSBB
Level II: Endoscopic band ligation can be considered
as a salvage treatment in case of acute bleeding from
small gastric varices when tissue adhesive is not
available
Level III: No adjustment
31 To prevent rebleeding from gastric varices, consideration should be given to addi-
tional glue injection (after 2 to 4 weeks), beta-blocker treatment or both combined
or TIPS. More data in this area are needed.
Level I: Best supportive care and NSBB
Level II: NSBB and endoscopic band ligation when
tissue adhesive or TIPS are not available
Level III: No adjustment
32 EVL or tissue adhesive can be used in bleeding from gastroesophageal varices type 1
(GOV1).
Level I: Best supportive care and NSBB
Level II: No adjustment
Level III: No adjustment
Early TIPS placement
33 An early TIPS with PTFE-covered stents within 72h (ideally < 24h) must be consid-
ered in patients bleeding from EV, GOV1 and GOV2at high risk of treatment failure
(e. g. Child-Pugh class C < 14 points or Child-Pugh class B with active bleeding) after
initial pharmacological and endoscopic therapy. Criteria for high-risk patients
should be refined.
Level I: Best supportive care and NSBB
Level II: Maximal endoscopic and pharmacological
therapy including NSBB whenTIPS is not available
Level III: No adjustment
Balloon tamponade
34 Balloon tamponade, given the high incidence of its severe adverse events, should
only be used in refractory oesophageal bleeding, as a temporary ‘‘bridge’’ (for a
maximum of 24h) with intensive care monitoring and considering intubation, until
definitive treatment can be instituted.
Level I: Best supportive care and NSBB
Level II: No adjustment
Level III: No adjustment
Use of self-expandable metal stents
35 Data suggest that self-expanding covered esophageal metal stents may be as effi-
cacious and a safer option than balloon tamponade in refractory oesophageal vari-
ceal bleeding.
Level I: Best supportive care and NSBB
Level II: No adjustment
Level III: No adjustment
Management of treatment failures
36 Persistent bleeding despite combined pharmacological and endoscopic therapy is
best managed by PTFE-covered TIPS.
Level I: Best supportive care and NSBB
Level II: Maximal endoscopic and pharmacological
therapy including NSBB whenTIPS is not available
Level III: No adjustment
37 Rebleeding during the first 5 days may be managed by a second attempt at endo-
scopic therapy. If rebleeding is severe, PTFE-covered TIPS is likely the best option.
Level I: Best supportive care and NSBB
Level II: Maximal endoscopic and pharmacological
therapy including NSBB whenTIPS is not available
Level III: No adjustment
Preventing recurrent variceal haemorrhage and other decompensating events
Prevention of recurrent variceal haemorrhage
38 First line therapy for all patients is the combination of NSBB (propranolol or nadolol)
+ EVL.
Level I: NSBB
Level II: No adjustment
Level III: No adjustment
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